Barbara Kropff

A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV

HCMV glycoprotein B subunit vaccine efficacy mediated by nonneutralizing antibody effector functions

De novo design of picomolar SARS-CoV-2 miniprotein inhibitors

Immunomodulatory Function of Interleukin 28B During Primary Infection With Cytomegalovirus

Cross-reactive Antibody Response between SARS-CoV-2 and SARS-CoV Infections

Mechanisms of SARS-CoV-2 entry into cells

Applying lessons learned from cytomegalovirus infection in transplant patients to vaccine design

Hepatitis C virus E1 and modified E2 delivered from an mRNA vaccine induces protective immunity

Development of cytomegalovirus vaccines: Prospects for prevention of congenital CMV infection

Global Mapping of O-Glycosylation of Varicella Zoster Virus, Human Cytomegalovirus, and Epstein-Barr Virus

Development and preclinical evaluation of an alphavirus replicon particle vaccine for cytomegalovirus

Human cytomegalovirus: clinical aspects, immune regulation, and emerging treatments

Role of the Microbiota in Immunity and Inflammation

Epidemiology of Community-Acquired Clostridium difficile-Associated Diarrhea

Human cytomegalovirus entry into cells

Clinical Practice Guidelines for Clostridium difficile Infection in Adults: 2010 Update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA)

Sensorineural hearing loss in children

A new era in cytomegalovirus vaccinology: considerations for rational design of next-generation vaccines to prevent congenital cytomegalovirus infection

Preconception Immunization with a Cytomegalovirus (CMV) Glycoprotein Vaccine Improves Pregnancy Outcome in a Guinea Pig Model of Congenital CMV Infection

Crystal Structure of the Human Cytomegalovirus Glycoprotein B

The Third International Consensus Guidelines on the Management of Cytomegalovirus in Solid-organ Transplantation

Global epidemiology of HIV infection in men who have sex with men

Rhesus monkeys for a nonhuman primate model of cytomegalovirus infections

HIV Superinfection

Impaired Peripheral Th1 CD4+ T Cell Response to Escherichia coli Proteins in Patients with Crohn’s Disease and Ankylosing Spondylitis

Glycoproteomics

Enhanced SARS-CoV-2 neutralization by dimeric IgA

Quantitation of human cytomegalovirus genomes in the brain of AIDS patients

Human Cytomegalovirus (HCMV) Infection of Endothelial Cells Promotes Naive Monocyte Extravasation and Transfer of Productive Virus To Enhance Hematogenous Dissemination of HCMV

Cytomegalovirus glycoprotein B-specific antibody analysis using electrochemiluminescence detection-based techniques

Donor-derived CMV-specific T cells reduce the requirement for CMV-directed pharmacotherapy after allogeneic stem cell transplantation

Human Coronaviruses and Other Respiratory Viruses: Underestimated Opportunistic Pathogens of the Central Nervous System?

Diagnosing COVID-19: The Disease and Tools for Detection

Vaccine innovations for emerging infectious diseases—a symposium report

Electrochemiluminescence (ECL)

Human cytomegalovirus (HCMV)‐specific T cell but not neutralizing or IgG binding antibody responses to glycoprotein complexes gB, gHgLgO, and pUL128L correlate with protection against high HCMV viral load reactivation in solid‐organ transplant recipients

Antibodies against the gH/gL/UL128/UL130/UL131 Complex Comprise the Majority of the Anti-Cytomegalovirus (Anti-CMV) Neutralizing Antibody Response in CMV Hyperimmune Globulin

Immune Correlates of Protection Against Human Cytomegalovirus Acquisition, Replication, and Disease

Human cytomegalovirus infection and expression in human malignant glioma.

Human Cytomegalovirus Glycoprotein B Nucleoside-Modified mRNA Vaccine Elicits Antibody Responses with Greater Durability and Breadth than MF59-Adjuvanted gB Protein Immunization

Protocol and Reagents for Pseudotyping Lentiviral Particles with SARS-CoV-2 Spike Protein for Neutralization Assays

Chemically Modified Bacterial Sacculi as a Vaccine Microparticle Scaffold

Protective capacity of neutralizing and non-neutralizing antibodies against glycoprotein B of cytomegalovirus

The Humoral Immune Response against Human Cytomegalovirus Is Characterized by a Delayed Synthesis of Glycoprotein-Specific Antibodies

An ELISA using recombinant proteins for the detection of neutralizing antibodies against human cytomegalovirus

Glycoprotein N of Human Cytomegalovirus Protects the Virus from Neutralizing Antibodies

Identification of the gene coding for rhesus cytomegalovirus glycoprotein B and immunological analysis of the protein.

Comparative analysis of fourteen individual human cytomegalovirus proteins for helper T cell response

Complex Formation by Human Cytomegalovirus Glycoproteins M (gpUL100) and N (gpUL73)

Epitope-Specific Humoral Responses to Human Cytomegalovirus Glycoprotein-B Vaccine With MF59: Anti-AD2 Levels Correlate With Protection From Viremia

The Carboxy-Terminal Domain of Glycoprotein N of Human Cytomegalovirus Is Required for Virion Morphogenesis

Protection from cytomegalovirus viremia following glycoprotein B vaccination is not dependent on neutralizing antibodies

A continuous sequence of more than 70 amino acids is essential for antibody binding to the dominant antigenic site of glycoprotein gp58 of human cytomegalovirus

Upregulation of CD40 Expression on Endothelial Cells Infected with Human Cytomegalovirus

Complex Formation by Glycoproteins M and N of Human Cytomegalovirus: Structural and Functional Aspects